irinotecan has been researched along with Kidney Diseases in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Budman, D; Byrd, J; Enders Klein, C; Fleming, G; Hohl, R; Hollis, D; Kastrissios, H; Leichman, CG; Marshall, J; Ramirez, J; Ratain, MJ; Rosner, GL; Venook, AP; Villalona, M | 1 |
| Fujimoto, K; Harada, T; Watanabe, K | 1 |
| Bishop, J; Clarke, SJ; Dodds, HM; Ong, SY; Rivory, LP | 1 |
1 trial(s) available for irinotecan and Kidney Diseases
| Article | Year |
|---|---|
A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Humans; Irinotecan; Kidney Diseases; Liver Diseases; Male; Middle Aged; Neoplasms; Pelvis; Radiotherapy | 2003 |
2 other study(ies) available for irinotecan and Kidney Diseases
| Article | Year |
|---|---|
[Favorable response obtained by low dose chemotherapy in an elderly patient with extensive small cell lung cancer and renal dysfunction].
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Humans; Irinotecan; Kidney Diseases; Lung Neoplasms; Male | 2005 |
Toxicity of irinotecan (CPT-11) and hepato-renal dysfunction.
Topics: Adenocarcinoma; Adenomatous Polyposis Coli Protein; Antineoplastic Agents, Phytogenic; Camptothecin; Cecal Neoplasms; Chemical and Drug Induced Liver Injury; Humans; Irinotecan; Kidney; Kidney Diseases; Liver; Liver Diseases; Liver Neoplasms; Male; Middle Aged; Topoisomerase I Inhibitors | 2001 |